Traders should view this as a near-term setback for SLNO, eliminating expected 2026 regulatory approval and commercialization in Europe. Monitor for future updates on re-engagement with EMA, but expect downward pressure on the stock due to lost market potential.
Price Chart
Executive Summary
Soleno Therapeutics has voluntarily withdrawn its marketing authorization application (MAA) for VIOKAT (VYKATTM XR) in Europe for Prader-Willi syndrome, citing business and strategic considerations. The decision preserves the option to re-engage with regulators in the future, but removes near-term commercial prospects in Europe.
Key Facts
- Soleno Therapeutics withdrew its MAA for VIOKAT (diazoxide choline) in Europe for Prader-Willi syndrome (PWS).
- The application was under review by the European Medicines Agency (EMA) with a decision expected in mid-2026.
- The withdrawal was voluntary and based on 'business and strategic considerations'.
- The company retains the ability to re-engage with regulators in the future if a viable pathway emerges.
Financial Impact
Removes potential European revenue from VIOKAT in 2026; delays or eliminates a key growth driver for the company.
Risk Factors
- Loss of European market opportunity for VIOKAT delays revenue diversification.
- Strategic uncertainty raises questions about management's commitment to international expansion.
- Potential perception of regulatory or commercial challenges underlying the withdrawal.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-144511 |
| Document: 0001193125-26-144511-index-headers.html | 0001193125-26-144511 |
| Document: 0001193125-26-144511-index.html | 0001193125-26-144511 |
| Document: 0001193125-26-144511.txt | 0001193125-26-144511 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 11, 2026 16w ago | Institutional Cluster | — | awaiting T+1 | — | — |
Jun 11, 2026 16w ago | Institutional Cluster | — | awaiting T+1 | — | — |
May 28, 2026 18w ago | 15-12G | — | awaiting T+1 | — | — |
May 28, 2026 18w ago | EFFECT | — | awaiting T+1 | — | — |
May 18, 2026 19w ago | 8-K / 25-NSE | $53.01 $53.01 | · 0.00% | ▲ +0.65% | — |
Apr 7, 2026 25w ago | 8-K | $52.35 $52.60 | ▼ −0.48% | ▲ +2.06% | — |
Apr 6, 2026 25w ago | 8-K | $52.25 $52.35 | ▲ +0.19% | ▲ +0.13% | — |
Mar 27, 2026 27w ago | Insider Cluster | $30.05 $30.44 | ▲ +1.30% | ▲ +1.66% | — |
Feb 26, 2026 31w ago | 8-K | $38.09 $39.07 | ▲ +2.57% | ▲ +3.03% | — |
Feb 25, 2026 31w ago | 8-K | $41.01 $38.09 | ▼ −7.12% | ▼ −6.57% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access